What Is Long COVID? Many people recover fully within a few days or weeks after being infected with SARS-CoV-2, the virus that causes COVID-19. But others have symptoms that linger for weeks, months, or even years after their initial diagnosis. Some people seem to recover from COVID-19 but then see their symptoms return, or they develop new symptoms within a few months. Even people who had no symptoms when they were infected can develop symptoms later. Either mild or severe COVID-19 can lead to long-lasting symptoms. Long COVID, long-haul COVID, post-COVID-19 condition, chronic COVID, and post-acute sequelae of SARS-CoV-2 (PASC) are all names for the health problems that some people experience within a few months of a COVID-19 diagnosis. Symptoms of long COVID may be the same or different than symptoms of COVID-19. Long COVID can also trigger other health conditions, such as diabetes or kidney disease.
For people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), “fatigue” doesn’t just mean being a little tired. It means a brain like molasses, a body exhausted and weak, and legs like jelly. If you are just tired, a typical remedy is to get some exercise or move around a bit to get blood flowing. But for people with ME/CFS, exercise does just the opposite. Physical or mental exertion can debilitate them, requiring recovery time that lasts for days, months, or years. Resting does not help. This symptom, known as post-exertional malaise, is one of the defining features of the disease, and it is poorly understood.
Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, Ph.D: “It is science at its hardest.” More New Online Views 8,944 Citations 0 25 Medical News & Perspectives July 8, 2022 COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value Rita Rubin, MA Article Information JAMA. Published online July 8, 2022. doi:10.1001/jama.2022.11252 related articles icon Related Articles Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, PhD: “It is science at its hardest.” The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection. The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection. Steve Gschmeissner/sciencesource.com The FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss whether to add an Omicron component to boosters for the fall. In order to have enough doses by early October, “we will need to very rapidly move to let companies know what that selection will be,” Marks reminded the panelists. (How many doses will be enough isn’t clear—as of June 30, only 51.1% of fully vaccinated US adults aged 18 years or older had received 1 booster shot, while only 27% of fully vaccinated adults aged 50 years or older, for whom a second booster is recommended, had received 2, according to government data.)
After multiple delays, very young children are finally eligible for COVID-19 vaccination. In mid-June, the Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Pfizer’s COVID-19 vaccine for children ages 6 months to 5 years, as well as to Moderna's vaccine for kids ages 6 months to 6 years. The Centers for Disease Control and Prevention (CDC) soon after recommended the vaccines, which should become available early next week.
Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age. For the Moderna COVID-19 Vaccine, the FDA amended the emergency use authorization (EUA) to include use of the vaccine in individuals 6 months through 17 years of age. The vaccine had been authorized for use in adults 18 years of age and older. For the Pfizer-BioNTech COVID-19 Vaccine, the FDA amended the EUA to include use of the vaccine in individuals 6 months through 4 years of age. The vaccine had been authorized for use in individuals 5 years of age and older.
IMPORTANCE Severeacuterespiratorysyndromecoronavirus2(SARS-CoV-2),theetiologyof coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.